Emergency delivery of lifesaving medicine inspires ABC fundraiser supporting rare disorder research
CONSHOHOCKEN, Pa. – The AmerisourceBergen Foundation and AmerisourceBergen associates on Thursday announced two donations totaling $32,000 to support rare disorder research. The donations were awarded to the Canadian Organization for Rare Disorders and the National Organization for Rare Disorders, two non-profit organizations devoted to identifying and treating rare disorders through patient services and education, advocacy and research programs.
The donations were inspired by a 13-hour, nearly 600-mile overnight truck delivery to provide lifesaving treatment to a newborn at a Toronto hospital on Christmas Day. On Dec. 23, 2015, ICS, a part of AmerisourceBergen, received a request to ship a specific medication to the hospital for a baby suffering from a rare condition that, if left untreated, could result in death. The prescribed medication is not traditionally available in Canada, so upon receiving the approval from Health Canada at mid-afternoon on Christmas Eve, the ICS team reopened its distribution center to process the order.
With no flights available, a team of ICS, World Courier and Innomar Strategies associates developed a plan to deliver the treatment within the tight timeframe. The plan, which included multiple drivers and several shipment handoffs, kicked off at 7:35 p.m. in Louisville, Ky. After receiving clearance at the Canadian border at 4:11 a.m., the final World Courier driver loaded the shipment and reached the hospital at 8:35 a.m., ultimately delivering the medication in time to save the baby’s life.
“Our associates’ commitment to overcoming obstacles and delivering the life-saving treatment in time underscores our patient-centered approach to healthcare,” said Doug Cook, president of Global Specialty Logistics at AmerisourceBergen. “We recognize that certain situations require unique solutions, and we’re able to leverage our resources and expertise to ensure patients receive the medication they need, when they need it.”
“Every day, we work to shape health care delivery, so we’re proud of how both our associates and the AmerisourceBergen Foundation responded to this lifesaving delivery and rallied to further support rare disorder research,” said Esperanza Neu, executive director of the AmerisourceBergen Foundation and VP workplace services, diversity and community relations at AmerisourceBergen. “We’re grateful that we can support leading non-profits as they pursue their mission to promote research, diagnosis and treatment for rare disorders.”
AmerisourceBergen has previously worked with CORD and NORD to further support rare disease research. Innomar Strategies, the leading Canadian service provider for specialty pharmaceuticals and a part of AmerisourceBergen, partners with CORD to bring awareness to rare disorders through a variety of events, including interactive seminars.
Lupin re-introduces Methergine tablets
BALTIMORE — Lupin on Thursday announced that it would be re-introducing its Methergine (methylergonovine maleate) tablets. The drug is indicated to manage uterine atony, hemorrhage and subinvolution of the uterus following delivery of the placenta, and for control of uterine hemorrhage in the second stage of labor. It's also the preferred treatment for postpartum hemorrhage, according to American Congress of Obstetricians and Gynecologists (ACOG) guidelines.
“The re-introduction of Methergine is a proud moment for Lupin, but also an important moment for expectant mothers across the country to feel confident in care options,” Lupin Pharmaceuticals president Paul McGarty said. “With Methergine, Lupin is making a significant investment to help improve the management of PPH, providing professional medical education, leveraging its specialized sales force to drive better awareness and access to care, and ensuring a more stable supply of this essential medicine.”
Lupin noted that one area where education is needed is in discerning accurate blood loss, which can be a barrier to optimal care. Underestimating blood loss can delay interventions and over-estimating can lead to such costly, unnecessary treatments as blood transfusions.
“Postpartum hemorrhage (PPH) is one of the most preventable causes of maternal mortality and it should be better managed in pursuit of improved patient care,” said Dr. David Schwartz, OBGYN and American Congress of Obstetricians and Gynecologists fellow, said. “I commend Lupin for spotlighting this public health issue and making an investment in treatment, education and awareness of PPH.”
Pharmacy First deploys Ateb med sync program ‘Time My Meds’
SHAWNEE MISSION, Kan. — Pharmacy First and Ateb on Thursday announced a partnership to offer Ateb's Time My Meds, an integrated medication synchronization solution, to Pharmacy First members.
By implementing Ateb's Time My Meds, Pharmacy First members will witness significant, measurable impact on increasing prescription fills and improving quality measures. Patients enrolled in Ateb's Time My Meds program reach above Medicare five-star PDC score thresholds for diabetes, hypertension and cholesterol, Ateb noted.
Ateb's solutions will enable Pharmacy First members to transition their pharmacies to the Appointment Based Model which increases patient engagement and provides the opportunity to offer additional paid services. Plus, by converting their pharmacy practices to a proactive workflow, pharmacies can predict when patients on chronic medications will visit the pharmacy for their prescription refills, thereby, improving inventory management. In addition to these benefits, pharmacies also have the ability to provide ongoing patient management through Ateb's online Patient Management Access Portal.
To complement the Time My Meds program, Pharmacy First members may also bundle Ateb's outbound notifications solution, which drives script growth and improves patient adherence through automated patient outreach methods. Based on the patient's preference, these notifications, displayed in real-time, are delivered via calls and text messages.
To see information about the potential impact of Ateb’s solution, see the infographic below.
Loading Post Please Wait...